Semaglutide Tied to Aging Clocks in HIV - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Semaglutide Tied to Aging Clocks in HIV

A posthoc analysis of a phase 2b trial found favorable changes in DNA methylation–based aging biomarkers among patients with human immunodeficiency virus–associated lipohypertrophy.

  • By

  • Andrea Surnit

  • June 9, 2026

  • 4 min

Share

Clinical Scorecard: Semaglutide Tied to Aging Clocks in HIV

At a Glance

CategoryDetail
ConditionHIV-associated lipohypertrophy
Key MechanismsSlower epigenetic aging associated with semaglutide treatment
Target PopulationPatients with HIV-1 infection, stable antiretroviral therapy, and clinical evidence of lipohypertrophy
Care SettingSingle-center, phase 2b randomized, double-blind, placebo-controlled trial

Key Highlights

  • Semaglutide associated with lower annualized epigenetic aging estimates compared to placebo
  • Largest differences observed in PhenoAge, SystemsAge, and PCGrimAge
  • 9% slower pace of aging measured by DunedinPACE
  • System-specific epigenetic measures favored semaglutide for several aging estimates
  • Findings are exploratory and require further prospective trials

Guideline-Based Recommendations

Diagnosis

  • Patients must have documented HIV-1 infection and clinical evidence of lipohypertrophy

Management

  • Semaglutide titrated from 0.25 mg to 1.0 mg once weekly

Monitoring & Follow-up

  • Assess epigenetic aging biomarkers at baseline and week 32

Risks

  • Exclusion of patients with diabetes or active cardiovascular disease

Patient & Prescribing Data

84 patients with HIV-associated lipohypertrophy

Semaglutide showed significant effects on epigenetic aging biomarkers

Clinical Best Practices

  • Consider patient eligibility criteria carefully
  • Monitor for changes in epigenetic biomarkers during treatment
  • Acknowledge the exploratory nature of findings

Related Resources & Content

Original Source(s)

Semaglutide Tied to Aging Clocks in HIV

  • by Andrea Surnit

  • June 9, 2026

Related Content

Hospital AI Fails to Flag Drug Diversion

"I've never myself seen these technologies be called out in that specific way"

Makary Resigns as FDA Commissioner Following Policy Disputes

Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization

Side Effects: Nobody Trained for This

Chemsex at the pharmacy counter. Gut bacteria tracking helmet impacts. PMD predicting psychiatric illness bidirectionally. This week's research keeps landing in the same uncomfortable place: medicine is improvising.